Salud financiera de hoja de balance de KALA BIO

Salud financiera controles de criterios 5/6

KALA BIO tiene un patrimonio de los accionistas total de $6.7M y una deuda total de $34.5M, lo que sitúa su ratio deuda-patrimonio en 518%. Sus activos y pasivos totales son $53.0M y $46.4M respectivamente.

Información clave

518.0%

Ratio deuda-patrimonio

US$34.50m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$48.48m
Patrimonio	US$6.66m
Total pasivo	US$46.37m
Activos totales	US$53.03m

Actualizaciones recientes sobre salud financiera

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Jul 07

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Apr 05

Recent updates

The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts

Aug 10

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Jul 07

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Apr 05

Kala Pharmaceuticals, Inc. (NASDAQ:KALA): When Will It Breakeven?

Mar 08

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($50.1M) de KALA superan a sus pasivos a corto plazo ($11.9M).

Pasivo a largo plazo: Los activos a corto plazo de KALA ($50.1M) superan a sus pasivos a largo plazo ($34.5M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: KALA tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de KALA ha crecido de 85.5% a 518% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: KALA tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: KALA dispone de suficiente cash runway para 1.1 años si el flujo de caja libre sigue creciendo a tasas históricas de 1% cada año.

Salud financiera de hoja de balance de KALA BIO

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Recent updates

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

Chairman & CEO notifies of intention to sell stock

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New minor risk - Share price stability

Price target decreased by 13% to US$26.00

Price target decreased by 9.7% to US$31.00

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Consensus forecasts updated

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Price target decreased to US$42.00

Price target decreased to US$90.67

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Kala Pharmaceuticals to execute reverse stock split

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kala Pharmaceuticals Q2 2022 Earnings Preview

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million.

Consensus revenue estimates fall by 27%

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Price target decreased to US$4.55

Insufficient new directors

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

Staying Patient With Kala Pharmaceuticals

Consensus revenue estimates fall to US$19.9m

The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts

Price target decreased to US$16.50

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

No longer forecast to breakeven

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Consensus forecasts updated

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Kala Pharmaceuticals Announces Preferred Position for Eysuvis™ on Cigna

Kala Pharmaceuticals, Inc. (NASDAQ:KALA): When Will It Breakeven?

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera